Attorney Docket No.: 6459.500-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Thim et al. Confirmation No. 4422

Serial No.: 10/685,368 Group Art Unit: 1654

Filed: October 14, 2003 Examiner: Gupta, Anish

For: GLP-2 Compounds, Formulations and Uses Thereof

PETITION UNDER 37 C.F.R. 1.47(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 35 U.S.C. § 116 and in accordance with 37 C.F.R. 1.47(a), Applicants, through the undersigned, hereby petition to make application for patent on behalf of themselves and unavailable inventor Niels Christian Kaarsholm, whose last known address is Clausholmvej 38, DK-2720, Vanloese, Denmark.

Submitted with this Petition are the following:

(1) Declaration of Lotte Lou, Coordinator in the Corporate Patents department of Novo Nordisk A/S, assignee of this application, setting forth the pertinent facts regarding the diligent efforts made by the assignee to reach Mr. Kaarsholm; and

(2) Copies of the original inventor declaration filed in this application, executed by Mr. Kaarsholm, and an assignment by Mr. Kaarsholm in favor of Novo Nordisk A/S of any rights in this patent application.

An investigation of inventorship, conducted, in part, in connection with the recent issued Notice of Allowance in this patent application, revealed that some of the originally named inventors should be removed and another person added (in view of claim amendments and other facts). Applicants concurrently file a new inventor declaration and other papers needed to make these changes in inventorship in the application. The Declaration of Ms. Lou establishes that in this process, despite her diligent efforts, Mr. Kaarsholm, who is no longer employed with the Assignee, could not be reached to execute the new inventor declaration. Applicants note that Mr. Kaarsholm executed the previous inventor declaration in association with this application and has assigned all of his rights in this application and related applications to Novo Nordisk A/S (documents evidencing these facts are also submitted herewith).

In view of the foregoing, Applicants respectfully submit that they have fulfilled the requirements of under 37 C.F.R. § 1.47 and 35 U.S.C. § 116 with respect to filing this application on their behalf as well as that of Mr. Kaarsholm (see Manual of Patent Examining Procedure § 409.03). Accordingly, Applicants request the Office to enter the new declaration and change of inventorship for this patent application.

The Commissioner is hereby authorized to charge the requisite fee of $200.00 for this petition, and to charge the payment of any additional fees associated with this communication or credit any overpayment, to Deposit Account 14-1447. A duplicate copy of this Petition is provided for that purpose.

Respectfully submitted,

Date: December 21, 2007

/Len S. Smith, Reg. No. #43139/
Len S. Smith, Reg. No. 43,139
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.
23650
PATENT TRADEMARK OFFICE